These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27716660)

  • 41. Comparison of escitalopram and paroxetine in the treatment of major depressive disorder.
    Lin HL; Hsu YT; Liu CY; Chen CH; Hsiao MC; Liu YL; Shen WW; Hsiao CF; Liu SI; Chang LH; Tang HS; Lai HL; Lin PS; Lin KM; Tsou HH
    Int Clin Psychopharmacol; 2013 Nov; 28(6):339-45. PubMed ID: 23881184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B; Andersen HF; Dolberg OT
    Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.
    von Knorring AL; Olsson GI; Thomsen PH; Lemming OM; Hultén A
    J Clin Psychopharmacol; 2006 Jun; 26(3):311-5. PubMed ID: 16702897
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Citalopram in the treatment of dysthymic disorder.
    Hellerstein DJ; Batchelder S; Miozzo R; Kreditor D; Hyler S; Gangure D; Clark J
    Int Clin Psychopharmacol; 2004 May; 19(3):143-8. PubMed ID: 15107656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects.
    Freedman M; Rewilak D; Xerri T; Cohen S; Gordon AS; Shandling M; Logan AG
    Neurology; 1998 Mar; 50(3):660-8. PubMed ID: 9521253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS.
    Mayer LS; Bay RC; Politis A; Steinberg M; Steele C; Baker AS; Rabins PV; Lyketsos CG
    Int J Geriatr Psychiatry; 2006 Oct; 21(10):930-6. PubMed ID: 16955427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial.
    Zuidersma M; Chua KC; Hellier J; Voshaar RO; Banerjee S;
    Am J Geriatr Psychiatry; 2019 Sep; 27(9):920-931. PubMed ID: 31084994
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive and psychomotor effects of three months of escitalopram treatment in elderly patients with major depressive disorder.
    Beheydt LL; Schrijvers D; Docx L; Bouckaert F; Hulstijn W; Sabbe B
    J Affect Disord; 2015 Dec; 188():47-52. PubMed ID: 26342888
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influences of the Big Five personality traits on the treatment response and longitudinal course of depression in patients with acute coronary syndrome: A randomised controlled trial.
    Kim SY; Stewart R; Bae KY; Kim SW; Shin IS; Hong YJ; Ahn Y; Jeong MH; Yoon JS; Kim JM
    J Affect Disord; 2016 Oct; 203():38-45. PubMed ID: 27280961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.
    Wang PN; Liao SQ; Liu RS; Liu CY; Chao HT; Lu SR; Yu HY; Wang SJ; Liu HC
    Neurology; 2000 Jun; 54(11):2061-6. PubMed ID: 10851363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
    Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
    Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial.
    Scantamburlo G; Hansenne M; Geenen V; Legros JJ; Ansseau M
    Eur Psychiatry; 2015 Jan; 30(1):65-8. PubMed ID: 25282363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study.
    Cumbo E; Cumbo S; Torregrossa S; Migliore D
    J Prev Alzheimers Dis; 2019; 6(3):192-197. PubMed ID: 31062834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation.
    Xiaoling Z; Yunping H; Yingdong L
    Pak J Pharm Sci; 2018 May; 31(3(Special)):1115-1118. PubMed ID: 29737292
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transcranial direct current stimulation for depression in Alzheimer's disease: study protocol for a randomized controlled trial.
    Narita Z; Yokoi Y
    Trials; 2017 Jun; 18(1):285. PubMed ID: 28629447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP).
    Takemoto M; Ohta Y; Hishikawa N; Yamashita T; Nomura E; Tsunoda K; Sasaki R; Tadokoro K; Matsumoto N; Omote Y; Abe K
    J Alzheimers Dis; 2020; 76(2):769-772. PubMed ID: 32568205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of escitalopram oxalate for patients with post-stroke depression.
    Xu JH; Jiang P
    Medicine (Baltimore); 2018 Apr; 97(14):e0219. PubMed ID: 29620632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative Analysis of the Effects of Escitalopram, Pramipexole, and Transcranial Magnetic Stimulation on Depression in Patients With Parkinson Disease: An Open-Label Randomized Controlled Trial.
    Chen J; Xu P; Guo X; Zou T
    Clin Neuropharmacol; 2022 Jul-Aug 01; 45(4):84-88. PubMed ID: 35652703
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
    Drye LT; Spragg D; Devanand DP; Frangakis C; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    PLoS One; 2014; 9(6):e98426. PubMed ID: 24914549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.